Creative Medical Technology Holdings Receives Notice of Allowance for ImmCelz™ for Treatment of Heart Failure and/or Post Infarct Pathological Remodeling
Rhea-AI Summary
Creative Medical Technology (NASDAQ: CELZ) has received a Notice of Allowance from the USPTO for a patent application covering their ImmCelz™ treatment for heart failure and post-infarct pathological remodeling. The patent, effective until at least 2040, will protect the company's proprietary treatment delivered through an ultra-minimally invasive outpatient procedure.
The potential market is significant, with over 5 million heart failure patients in the United States and an additional 6 million patients with chronic chest pain who could benefit from the treatment. The patent strengthens Creative Medical's intellectual property portfolio in regenerative medicine and cell-based therapies.
Positive
- Patent protection secured until at least 2040 for ImmCelz treatment
- Large addressable market of over 11 million potential patients in the US
- Treatment delivered through ultra-minimally invasive outpatient procedure
- Strengthens company's intellectual property portfolio in regenerative medicine
Negative
- Product still in clinical-stage, not yet FDA approved
- No revenue generation from this treatment currently
News Market Reaction – CELZ
In the trading session that priced this news, CELZ gained 1.39%, reflecting a mild positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
AI-generated analysis. How Rhea-AI works. Not financial advice.
PHOENIX, July 11, 2025 (GLOBE NEWSWIRE) -- Creative Medical Technology Holdings, Inc. (NASDAQ: CELZ) (“Creative Medical” or the “Company”), a clinical-stage biotechnology company specializing in regenerative medicine, today announced that it has received a Notice of Allowance from the United States Patent and Trademark Office (USPTO) for a U.S. patent application titled, “Treatment Of Heart Failure And/Or Post Infarct Pathological Remodeling By Ex Vivo Reprogrammed Immune Cells.”
Once granted, the patent will be in effect until at least 2040.
The patent has broad claims to treat patients who are at risk of developing or who already have heart failure with the Company’s proprietary ImmCelz product. Some patients who experience a heart attack develop post-infarct pathological remodeling, which can lead to reduced heart function and potentially result in heart failure. The total treatable heart failure population in the United States is greater than five million patients. There are also over six million patients who have chronic chest pain (refractory angina) despite maximal medical and surgical therapy who may also benefit from the ImmCelz product. The ImmCelz product is delivered to the patient via an ultra-minimally invasive outpatient procedure.
"This Notice of Allowance further strengthens our already robust intellectual property portfolio and reflects the potential of our cell-based technology to develop therapies that support the reprogramming, regrowth, and repair of the body across multiple indications,” said Timothy Warbington, CEO of Creative Medical. “This latest allowance adds further value to our franchise and will help to support the continuing growth and evolution of our regenerative medicine platform."
About ImmCelzTM
Creative Medical’s ImmCelz platform utilizes a patient’s own extracted immune cells that are then “reprogrammed/supercharged” by culturing them outside the patient’s body with optimized cell-free factors. The immune cells are then re-injected into the patient from whom they were extracted. The Company believes that this process endows the immune cells with regenerative properties (or “supercharges” them) on top of their original innate functions providing them with the ability to treat multiple indications.
About Creative Medical Technology Holdings
Creative Medical Technology Holdings, Inc. (NASDAQ: CELZ) is a clinical-stage biotechnology company pioneering regenerative medicine solutions for multiple indications, including pain management, neurology, and urology. The company leverages cutting-edge cell therapy technologies to develop transformative treatments aimed at improving patient outcomes.
For more information, visit www.creativemedicaltechnology.com.
Forward Looking Statements
This news release may contain forward-looking statements including, but not limited to, comments regarding the potential for the Company’s cell-based therapies and the strength of its intellectual property portfolio. Forward-looking statements address future events and conditions and, therefore, involve inherent risks and uncertainties. Actual results may differ materially from those currently anticipated in such statements. See the periodic and other reports filed by Creative Medical Technology Holdings, Inc. with the Securities and Exchange Commission and available on the Commission's website at www.sec.gov.
Contact:
Creative Medical Technology Holdings, Inc.
IR@CreativeMedicalTechnology.com
Investor Relations:
Devin Sullivan, Managing Director
The Equity Group Inc.
dsullivan@equityny.com
Conor Rodriguez
Associate
crodriguez@equityny.com
